Brain Sciences
August 21, 2025
Dean Bilenker, Nicole M. Avena
2 citations
Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive and behavioral rigidity. This review examines the rationale for using serotonergic psychedelics—particularly 5-HT2A receptor agonists such as psilocybin—in the treatment of eating disorders (EDs), including anorexia nervosa (AN), bulimia nervosa (BN),...
Psychopharmacology
August 11, 2025
Jussi Jylkkä, Aila Mustamo
1 citation
RATIONALE: Anecdotal evidence suggests that psychedelic researchers often have personal experiences with psychedelic substances. While such experiences may benefit research, concerns have been raised about potential biases and "excessive enthusiasm." However, the prevalence of personal experiences, their perceived relevance, and their association with opinions about psychedelics remain...
Current Neurology and Neuroscience Reports
August 9, 2025
James J H Im, Claire H Sandoe
Psychedelics are often queried as a potential therapeutic option in a multitude of conditions, including pain and mental health disorders, with a growing body of patient reports and scientific publications describing potential benefit. This article reviews recent research on psychedelic compounds for treatment of headache disorders. Observational data, case reports, and a few recent small,...
Journal of Psychoactive Drugs
August 4, 2025
Meredith C Meacham, Maha N. Mian, Ralph C. Wang et al.
2 citations
Interest in and use of hallucinogens appears to be growing in the United States, yet less is known about the use of multiple hallucinogens. The aims of this study are to characterize subgroups of lifetime hallucinogen use and to identify sociodemographic correlates of these subgroups. Latent class models were fit using 2021-2022 National Survey on Drug Use and Health (NSDUH) data on a...
Journal of Eating Disorders
July 24, 2025
Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz et al.
2 citations
There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders ("MED-FED") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact on ED symptoms and general mental...
Journal of Clinical Psychopharmacology
July 21, 2025
Guy Ludbrook, Nathan Bryson, Beatrix Taylor et al.
2 citations
This study is the first to formally evaluate in humans the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RE104, a prodrug of the synthetic psychedelic known as 4-hydroxy-N,N-diisopropyltryptamine or 4-OH-DiPT. This double-blind, randomized, placebo-controlled, phase 1 study of single subcutaneous (SC) doses of RE104 (5 to 40 mg) included 6 cohorts and a total of 48...
Annals of the New York Academy of Sciences
July 21, 2025
Marcel Socoró-garrigosa, Yonatan Sanz Perl, Morten L. Kringelbach et al.
3 citations
Abstract Determining the scale of neural representations is a central challenge in neuroscience. While localized representations have traditionally dominated, evidence suggests information is also encoded in distributed, hierarchical networks. Recent research indicates that the hierarchy of causal influences shaping functional patterns serves as a signature of distinct brain states, with...
AJOB empirical bioethics
July 16, 2025
Katherine Cheung, Caleigh Propes, Marianna Graziosi et al.
4 citations
Classic psychedelics, such as psilocybin and LSD, evoke certain kinds of altered states of consciousness. Specific features of the experience, such as its allegedly ineffable nature, have been discussed as posing challenges to the informed consent process. A growing call for tailored informed consent documents (ICDs) in the psychedelic bioethics literature raises the question of how closely...
Australian & New Zealand Journal of Psychiatry
July 15, 2025
Zohaib Nadeem, Stephen Parker, Hugh McGovern et al.
7 citations
Background: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and psilocybin for treatment-resistant depression. However, limited data exists on Australian mental healthcare providers’ attitudes, knowledge and readiness to implement with psychedelic-assisted psychotherapy. Methods: A cross-sectional survey was...
Current microbiology
July 15, 2025
Gokul Sudhakaran, Shreya Chakraborty, Ashok Kumar et al.
2 citations
Psilocybe species, commonly known as "magic mushrooms", are a group of hallucinogenic fungi known for their psychoactive compounds such as psilocybin, psilocin, baeocystin, and norbaeocystin. These species have been the focus of scientific study due to their potential therapeutic applications, despite their classification as controlled substances in many jurisdictions. This review aims to...